A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours-Reference-Cited by-同舟云学术

A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours

Published:2018-10-15 Issue:10 Volume:119 Page:1200-1207
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Maity Amit,Mick Rosemarie,Huang Alexander C.,George Sangeeth M.,Farwell Michael D.,Lukens John N.,Berman Abigail T.,Mitchell Tara C.,Bauml Josh,Schuchter Lynn M.,O’Hara Mark,Lin Lilie L.,Demichele Angela,Christodouleas John P.,Haas Naomi B.,Patsch Dana M.,Hahn Stephen M.,Minn Andy J.,Wherry E. John,Vonderheide Robert H.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0281-9.pdf

Reference33 articles.

1. Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).

2. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24, 207–212 (2012).

3. Gandhi, S. J. et al. Awakening the immune system with radiation: Optimal dose and fractionation. Cancer Lett. 368, 185–190 (2015).

4. Vanpouille-Box, C., Formenti, S. C. & Demaria, S. Toward precision radiotherapy for use with immune checkpoint blockers. Clin. Cancer Res. 24, 259–265 (2018).

5. Weichselbaum, R. R., Liang, H., Deng, L. & Fu, Y. X. Radiotherapy and immunotherapy: a beneficial liaison? Nat. Rev. Clin. Oncol. 14, 365–379 (2017).

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and tolerability of radiotherapy in combination with systemic targeted therapies for treatment of hepatocellular carcinoma: a narrative review;Chinese Clinical Oncology;2024-06

2. Immunotherapy and Radiotherapy Combinations for Sarcoma;Seminars in Radiation Oncology;2024-04

3. The abscopal effect: mechanism of occurrence and prospects of using it in therapy of metastatic cancer;Siberian journal of oncology;2024-03-20

4. Design of a single-center, phase II trial to explore the efficacy and safety of ‘R-ISV-RO’ treatment in advanced tumors;Future Oncology;2024-03-06

5. Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study);BMJ Open;2024-03